Registration Header

Translational Applications of MiniPDX: An In Vivo Organoid Assay in New Drug R&D

Live Date:11/18/2021

Duration:60 minutes

LIDE’s novel MiniPDX is a 7-day, in vivo drug efficacy test for oncology therapeutics.  It is the in vivo version of a 3D organoid assay and correlates with traditional PDX by 92%, and with clinical end point at 82%. These high correlations make MiniPDX an effective option to test targeted drugs, chemotherapies, angiogenesis drugs, and more, while demonstrating superior testing times and cost-effectiveness versus traditional PDX.  In a clinical setting, MiniPDX, together with next-generation sequencing (NGS), is playing an emerging role in personalized oncology. 

The process starts with a freshly prepared cell suspension from either a clinical sample or PDX (Patient Derived Xenograft) model. This sample is sealed into a mini capsule with 500 KD cut-off pores.  Capsules are implanted into SCID mice subcutaneously, and a test compound is given systemically for 7 days.  The efficacy of the test compound is then evaluated by measuring ATP of the cancer cells in the capsule.

The MiniPDX mouse trial can also be coupled with “K-Cell Omic” analysis (DNA, RNA, and Protein), presenting a powerful tool for the identification of drug candidates and the discovery of companion diagnostic markers. 

Key learning objectives:

  • Understand how MiniPDX + Omics analysis empowers precision medicine
  • Pros and cons of functional diagnosis assays (CR, Organoid, MiniPDX, PDX)
  • How to leverage MiniPDX + Omics for the identification of drug candidates
  • Role of K Cell RNAseq + FGI (Functional Genomic Imaging)
  • LIDE's PMed Trial database for AI aided drug discovery

Click the button below to access the login portal:



Dr. Danyi Wen

Founder, President & CEO

LIDE Biotech

Dr. Wen’s research foundation was 12 years at Millennium Pharmaceutical, Biogen-Idec in Boston, MA. In 2007, attracted by the innovation coming from overseas, she returned to China as VP of Biology at Shanghai ChemPartner. She founded Shanghai LIDE Biotech in 2011 to drive research and development in personalized precision medicine. She maintains strong alliances in the academic space and serves as adjourn professor of Beijing Xiehe Hospital and School of Pharmacy of Fudan University and an instructor at Shanghai Technology University. She is a key opinion leader in the drug development space, serving as editor of “Progress in Pharmaceutical Sciences”, Director of PhiRDA, CRO Sub-Group and President of SDDA (Sino-Drug Discovery Association). She is also an Associate of Chinese anti-cancer Association (society of Liver, bile, Pancreatic); Vice Group Leader of CMBA Tissue Bank Society and PDX Group.
First Name
Last Name
Email Address
Job Title
What are you hoping to get out of this webinar?
Yes, I approve the webinar sponsor(s) to send me emails about relevant events, products, services, and promotions that may be of interest to me.

Yes, I agree to InsideScientific’s Privacy Policy, and in support of accessing free scientific webinars, virtual events, and educational content, I agree to receive emails from InsideScientific about programs of similar scientific subject to this webinar.

By completing and submitting this registration, you acknowledge that your personal data collected in this form will be processed by InsideScientific in accordance with our privacy policy.  In addition, you agree to receive e-mail communication from InsideScientific about this webinar and other news that is of similar research or scientific topic.  You may opt out of emails at any time. By completing this registration you confirm that you have read and agree to the associated Privacy Policies linked below.